Oncopeptides AB (publ) (LON:0RN4)

Oncopeptides AB Statistics

Total Valuation

Oncopeptides AB has a market cap or net worth of GBP 63.53 million. The enterprise value is 63.60 million.

Market Cap	63.53M
Enterprise Value	63.60M

Important Dates

The next estimated earnings date is Thursday, February 19, 2026.

Earnings Date	Feb 19, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	258.57M
Shares Outstanding	n/a
Shares Change (YoY)	+58.45%
Shares Change (QoQ)	+7.65%
Owned by Insiders (%)	0.70%
Owned by Institutions (%)	13.70%
Float	229.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	12.88
PB Ratio	123.08
P/TBV Ratio	123.08
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-3.01
EV / Sales	12.52
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.53

Financial Position

The company has a current ratio of 3.42, with a Debt / Equity ratio of 22.75.

Current Ratio	3.42
Quick Ratio	3.27
Debt / Equity	22.75
Debt / EBITDA	n/a
Debt / FCF	-0.65
Interest Coverage	-7.60

Financial Efficiency

Return on equity (ROE) is -376.73% and return on invested capital (ROIC) is -75.21%.

Return on Equity (ROE)	-376.73%
Return on Assets (ROA)	-57.86%
Return on Invested Capital (ROIC)	-75.21%
Return on Capital Employed (ROCE)	-158.10%
Weighted Average Cost of Capital (WACC)	-0.65%
Revenue Per Employee	65,756
Profits Per Employee	-281,949
Employee Count	75
Asset Turnover	0.24
Inventory Turnover	0.20

Taxes

In the past 12 months, Oncopeptides AB has paid 80,688 in taxes.

Income Tax	80,688
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +89.57% in the last 52 weeks. The beta is -1.49, so Oncopeptides AB's price volatility has been lower than the market average.

Beta (5Y)	-1.49
52-Week Price Change	+89.57%
50-Day Moving Average	4.52
200-Day Moving Average	3.97
Relative Strength Index (RSI)	23.30
Average Volume (20 Days)	29,674

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncopeptides AB had revenue of GBP 4.93 million and -21.15 million in losses. Loss per share was -0.10.

Revenue	4.93M
Gross Profit	4.83M
Operating Income	-19.39M
Pretax Income	-21.07M
Net Income	-21.15M
EBITDA	-19.19M
EBIT	-19.39M
Loss Per Share	-0.10

Balance Sheet

The company has 11.68 million in cash and 11.75 million in debt, with a net cash position of -67,187.

Cash & Cash Equivalents	11.68M
Total Debt	11.75M
Net Cash	-67,187
Net Cash Per Share	n/a
Equity (Book Value)	516,182
Book Value Per Share	0.00
Working Capital	10.69M

Cash Flow

In the last 12 months, operating cash flow was -17.99 million and capital expenditures -28,186, giving a free cash flow of -18.02 million.

Operating Cash Flow	-17.99M
Capital Expenditures	-28,186
Free Cash Flow	-18.02M
FCF Per Share	n/a

Margins

Gross Margin	97.88%
Operating Margin	-393.09%
Pretax Margin	-427.15%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oncopeptides AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-58.45%
Shareholder Yield	-58.45%
Earnings Yield	-33.28%
FCF Yield	-28.37%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3